Morphine-induced alterations of immune status are blocked by the dopamine D2-like receptor agonist 7-OH-DPAT

Journal of Neuroimmunology

Volumn 148, Issue 1-2, 2004, Pages 54-62

  Saurer, Timothy B ^a   Carrigan, Kelly A ^a   Ijames, Stephanie G ^a   Lysle, Donald T ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

7 OH DPAT; Dopamine; Immunomodulation; Lymphocyte proliferation; Morphine; Natural killer cell activity

Indexed keywords

2 DIPROPYLAMINO 7 HYDROXYTETRALIN; DOPAMINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; IMMUNOMODULATING AGENT; MORPHINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOPAMINERGIC SYSTEM; IMMUNE STATUS; IMMUNOMODULATION; IMMUNOPATHOLOGY; LYMPHOCYTE PROLIFERATION; MALE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM;

EID: 1242340284     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2003.11.006     Document Type: Article

References (68)

1. Bayer B.M., Daussin S., Hernandez M., Irvin L. Morphine inhibition of lymphocyte activity is mediated by an opioid dependent mechanism. Neuropharmacology. 29:1990;369-374.
2. Bayer B.M., Hernandez M., Irvin L. Suppression of lymphocyte activity after acute morphine administration appears to be glucocorticoid independent. Prog. Clin. Biol. Res. 325:1990;273-282.
3. Bayer B.M., Mulroney S.E., Hernandez M.C., Ding X.Z. Acute infusions of cocaine result in time- and dose-dependent effects on lymphocyte responses and corticosterone secretion in rats. Immunopharmacology. 29:1995;19-28.
4. Becker A., Grecksch G., Kraus J., Peters B., Schroeder H., Schulz S., Hollt V. Loss of locomotor sensitisation in response to morphine in D1 receptor deficient mice. Naunyn-Schmiedebergs Arch. Pharmacol. 363:2001;562-568.
5. Bieganowska K., Czonkowska A., Korlak J. Pargyline pretreatment prevents immunological changes induced by MPTP in mice. Immunopharmacology. 35:1996;149-154.
6. Brown S.M., Stimmel B., Taub R.N., Kochwa S., Rosenfield R.E. Immunologic dysfunction in heroin addicts. Arch. Intern. Med. 134:1974;1001-1006.
7. Bryant H.U., Bernton E.W., Holaday J.W. Morphine pellet-induced immunomodulation in mice: temporal relationships. J. Pharmacol. Exp. Ther. 245:1988;913-920.
8. Burris K.D., Pacheco M.A., Filtz T.M., Kung M.P., Kung H.F., Molinoff P.B. Lack of discrimination by agonists for D2 and D3 dopamine receptors. Neuropsychopharmacology. 12:1995;335-345.
9. Carr D.J., Gebhardt B.M., Paul D. Alpha adrenergic and mu-2 opioid receptors are involved in morphine-induced suppression of splenocyte natural killer activity. J. Pharmacol. Exp. Ther. 264:1993;1179-1186.
10. Carr D.J., Mayo S., Gebhardt B.M., Porter J. Central alpha-adrenergic involvement in morphine-mediated suppression of splenic natural killer activity. J. Neuroimmunol. 53:1994;53-63.
11. Cook C.D., Picker M.J. Dopaminergic activity and the discriminative stimulus effects of mu opioids in pigeons: importance of training dose and attenuation by the D3 agonist (±)-7-OH-DPAT. Psychopharmacology (Berl.). 136:1998;59-69.
12. Cook C.D., Rodefer J.S., Picker M.J. Selective attenuation of the antinociceptive effects of mu opioids by the putative dopamine D-3 agonist 7-OH-DPAT. Psychopharmacology. 144:1999;239-247.
13. Daly S.A., Waddington J.L. Behavioural effects of the putative D-3 dopamine receptor agonist 7-OH-DPAT in relation to other "D-2-like" agonists. Neuropharmacology. 32:1993;509-510.
14. Deleplanque B., Vitiello S., Le Moal M., Neveu P.J. Modulation of immune reactivity by unilateral striatal and mesolimbic dopaminergic lesions. Neurosci. Lett. 166:1994;216-220.
15. Devoino L., Alperina E., Galkina O., Ilyutchenok R. Involvement of brain dopaminergic structures in neuroimmunomodulation. Int. J. Neurosci. 91:1997;213-228.
16. Dichiara G., Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. U. S. A. 85:1988;5274-5278.
17. Donahoe R.M., Nicholson J.K., Madden J.J., Donahoe F., Shafer D.A., Gordon D., Bokos P., Falek A. Coordinate and independent effects of heroin, cocaine, and alcohol abuse on T-cell E-rosette formation and antigenic marker expression. Clin. Immunol. Immunopathol. 41:1986;254-264.
18. Fecho K., Dykstra L.A., Lysle D.T. Evidence for beta-adrenergic-receptor involvement in the immunomodulatory effects of morphine. J. Pharmacol. Exp. Ther. 265:1993;1079-1087.
19. Fecho K., Maslonek K.A., Dykstra L.A., Lysle D.T. Assessment of the involvement of central nervous system and peripheral opioid receptors in the immunomodulatory effects of acute morphine treatment in rats. J. Pharmacol. Exp. Ther. 276:1996;626-636.
20. Fecho K., Maslonek K.A., Dykstra L.A., Lysle D.T. Evidence for sympathetic and adrenal involvement in the immunomodulatory effects of acute morphine treatment in rats. J. Pharmacol. Exp. Ther. 277:1996;633-645.
21. Freire-Garabal M., Balboa J.L., Nunez M.J., Castano M.T., Llovo J.B., Fernandez-Rial J.C., Belmonte A. Effects of amphetamine on T-cell immune response in mice. Life Sci. 49:1991;L107-L112.
22. Gilbert D.B., Cooper S.J. 7-OH-DPAT injected into the accumbens reduces locomotion and sucrose ingestion: D3 autoreceptor-mediated effects? Pharmacol. Biochem. Behav. 52:1995;275-280.
23. Gilbert D.B., Millar J., Cooper S.J. The putative dopamine D-3 agonist, 7-OH-DPAT, reduces dopamine release in the nucleus-accumbens and electrical self-stimulation to the ventral tegmentum. Brain Res. 681:1995;1-7.
24. Gysling K., Wang R.Y. Morphine-induced activation of A10 dopamine neurons in the rat. Brain Res. 277:1983;119-127.
25. Hernandez M.C., Flores L.R., Bayer B.M. Immunosuppression by morphine is mediated by central pathways. J. Pharmacol. Exp. Ther. 267:1993;1336-1341.
26. Hopf F.W., Cascini M.G., Gordon A.S., Diamond I., Bonci A. Cooperative activation of dopamine D1 and D2 receptors increases spike firing of nucleus accumbens neurons via G-protein betagamma subunits. J. Neurosci. 23:2003;5079-5087.
27. Hung C.Y., Lefkowitz S.S., Geber W.F. Interferon inhibition by narcotic analgesics. Proc. Soc. Exp. Biol. Med. 142:1973;106-111.
28. Hussey H.H., Katz S. Infections resulting from narcotic addiction: report of 102 cases. Am. J. Med. 9:1950;186-193.
29. Kalivas P.W., Stewart J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res. Brain Res. Rev. 16:1991;223-244.
30. Koeltzow T.E., Xu M., Cooper D.C., Hu X.T., Tonegawa S., Wolf M.E., White F.J. Alterations in dopamine release but not dopamine autoreceptor function in dopamine D3 receptor mutant mice. J. Neurosci. 18:1998;2231-2238.
31. Lejeune F., Millan M.J. Activation of dopamine D3 autoreceptors inhibits firing of ventral tegmental dopaminergic neurons in vivo. Eur. J. Pharmacol. 275:1995;R7-R9.
32. Leone P., Pocock D., Wise R.A. Morphine-dopamine interaction - ventral tegmental morphine increases nucleus-accumbens dopamine release. Pharmacol. Biochem. Behav. 39:1991;469-472.
33. Levant B. The D3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol. Rev. 49:1997;231-252.
34. Levant B., Bancroft G.N., Selkirk C.M. In vivo occupancy of D2 dopamine receptors by 7-OH-DPAT. Synapse. 24:1996;60-64.
35. Levite M., Chowers Y., Ganor Y., Besser M., Hershkovits R., Cahalon L. Dopamine interacts directly with its D3 and D2 receptors on normal human T cells, and activates beta1 integrin function. Eur. J. Immunol. 31:2001;3504-3512.
36. Liang-Suo J., Gomez-Flores R., Weber R.J. Immunosuppression induced by central action of morphine is not blocked by mifepristone (RU 486). Life Sci. 71:2002;2595-2602.
37. Lockwood L.L., Silbert L.H., Fleshner M., Laudenslager M.L., Watkins L.R., Maier S.F. Morphine-induced decreases in in vivo antibody responses. Brain Behav. Immun. 8:1994;24-36.
38. Louria D.B., Hensle T., Rose J. The major medical complications of heroin addiction. Ann. Intern. Med. 67:1967;1-22.
39. Luttgens W.F. Endocarditis in "main line" opium addicts. Arch. Intern. Med. 83:1949;653-664.
40. Lysle D.T., Coussons M.E., Watts V.J., Bennett E.H., Dykstra L.A. Morphine-induced alterations of immune status - dose dependency, compartment specificity and antagonism by naltrexone. J. Pharmacol. Exp. Ther. 265:1993;1071-1078.
41. Lysle D.T., Hoffman K.E., Dykstra L.A. Evidence for the involvement of the caudal region of the periaqueductal gray in a subset of morphine-induced alterations of immune status. J. Pharmacol. Exp. Ther. 277:1996;1533-1540.
42. Mcdonough R.J., Madden J.J., Falek A., Shafer D.A., Pline M., Gordon D., Bokos P., Kuehnle J.C., Mendelson J. Alteration of lymphocyte-T and null lymphocyte frequencies in the peripheral-blood of human opiate addicts - in vivo evidence for opiate receptor-sites on lymphocytes-T. J. Immunol. 125:1980;2539-2543.
43. Missale C., Nash S.R., Robinson S.W., Jaber M., Caron M.G. Dopamine receptors: from structure to function. Physiol. Rev. 78:1998;189-225.
44. Nelson C.J., Dykstra L.A., Lysle D.T. Comparison of the time course of morphine's analgesic and immunologic effects. Anesth. Analg. 85:1997;620-626.
45. Nistico G., Caroleo M.C., Arbitrio M., Pulvirenti L. Evidence for an involvement of dopamine D1 receptors in the limbic system in the control of immune mechanisms. Neuroimmunomodulation. 1:1994;174-180.
46. Novick D.M., Ochshorn M., Ghali V., Croxson T.S., Mercer W.D., Chiorazzi N., Kreek M.J. Natural-killer cell-activity and lymphocyte subsets in parenteral heroin abusers and long-term methadone-maintenance patients. J. Pharmacol. Exp. Ther. 250:1989;606-610.
47. Nowycky M.C., Walters J.R., Roth R.H. Dopaminergic neurons: effect of acute and chronic morphine administration on single cell activity and transmitter metabolism. J. Neural. Transm. 42:1978;99-116.
48. Nunez-Iglesias M.J., Castro-Bolano C., Losada C., Pereiro-Raposo M.D., Riveiro P., Sanchez-Sebio P., Mayan-Santos J.M., Rey-Mendez M., Freire-Garabal M. Effects of amphetamine on cell mediated immune response in mice. Life Sci. 58:1996;L-33.
49. Ochshorn M., Novick D.M., Kreek M.J. Invitro studies of the effect of methadone on natural-killer-cell activity. Israel J. Med. Sci. 26:1990;421-425.
50. Ostrowski N.L., Hatfield C.B., Caggiula A.R. The effects of low doses of morphine on the activity of dopamine-containing cells and on behavior. Life Sci. 31:1982;2347-2350.
51. Ouagazzal A.M., Creese I. Intra-accumbens infusion of D(3) receptor agonists reduces spontaneous and dopamine-induced locomotion. Pharmacol. Biochem. Behav. 67:2000;637-645.
52. Patel J., Trout S.J., Palij P., Whelpton R., Kruk Z.L. Biphasic inhibition of stimulated endogenous dopamine release by 7-OH-DPAT in slices of rat nucleus-accumbens. Br. J. Pharmacol. 115:1995;421-426.
53. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1986;Academic Press, San Diego.
54. Piazza P.V., Le Moal M. The role of stress in drug self-administration. Trends Pharmacol. Sci. 19:1998;67-74.
55. Plaznik A., Stefanski R., Kostowski W. Interaction between accumbens D1 and D2 receptors regulating rat locomotor activity. Psychopharmacology (Berl.). 99:1989;558-562.
56. Pross H.F., Maroun J.A. The standardization of Nk cell assays for use in studies of biological response modifiers. J. Immunol. Methods. 68:1984;235-249.
57. Ricci A., Mariotta S., Greco S., Bisetti A. Expression of dopamine receptors in immune organs and circulating immune cells. Clin. Exp. Hypertens. 19:1997;59-71.
58. Rodriguez D.F., Rubio P., Martin-Calderon J.L., Caine S.B., Koob G.F., Navarro M. The dopamine receptor agonist 7-OH-DPAT modulates the acquisition and expression of morphine-induced place preference. Eur. J. Pharmacol. 274:1995;47-55.
59. Sacerdote P., Manfredi B., Mantegazza P., Panerai A.E. Antinociceptive and immunosuppressive effects of opiate drugs: a structure-related activity study. Br. J. Pharmacol. 121:1997;834-840.
60. Santambrogio L., Lipartiti M., Bruni A., Dal Toso R. Dopamine receptors on human T- and B-lymphocytes. J. Neuroimmunol. 45:1993;113-119.
61. Shavit Y., Depaulis A., Martin F.C., Terman G.W., Pechnick R.N., Zane C.J., Gale R.P., Liebeskind J.C. Involvement of brain opiate receptors in the immune-suppressive effect of morphine. Proc. Natl. Acad. Sci. U. S. A. 83:1986;7114-7117.
62. Shippenberg T.S., Herz A. Place preference conditioning reveals the involvement of D1-dopamine receptors in the motivational properties of mu- and kappa-opioid agonists. Brain Res. 436:1987;169-172.
63. Stoof J.C., Kebabian J.W. Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum. Nature. 294:1981;366-368.
64. Suzuki T., Maeda J., Funada M., Misawa M. The D3-receptor agonist (±)-7-hydroxy-N,N-di-n-propyl-2-aminotetralin (7-OH-DPAT) attenuates morphine-induced hyperlocomotion in mice. Neurosci. Lett. 187:1995;45-48.
65. Weber R.J., Pert A. The periaqueductal gray-matter mediates opiate-induced immunosuppression. Science. 245:1989;188-190.
66. Xu M., Koeltzow T.E., Cooper D.C., Tonegawa S., White F.J. Dopamine D3 receptor mutant and wild-type mice exhibit identical responses to putative D3 receptor-selective agonists and antagonists. Synapse. 31:1999;210-215.
67. Yaksh T.L., Yeung J.C., Rudy T.A. Systematic examination in the rat of brain sites sensitive to the direct application of morphine: observation of differential effects within the periaqueductal gray. Brain Res. 114:1976;83-103.
68. Zarrindast M.R., Rezayof A., Sahraei H., Haeri-Rohani A., Rassouli Y. Involvement of dopamine D1 receptors of the central amygdala on the acquisition and expression of morphine-induced place preference in rat. Brain Res. 965:2003;212-221.